Pure Global
NCT06309355

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

A Randomized, Placebo-controlled, Double-blind, Multi Center, Phase IIa Trial Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of Topical Ointment YR001 in Adult Patients With Mild to Moderate Atopic Dermatitis
Hangzhou Yirui Pharmaceutical Technology Co., Ltd·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
YR001 ointment
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Location
Baton Rouge, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Jun 01, 2025
Enrollment
36 participants
Primary outcome

The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50.

Summary

This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical
 ointment in adult patients with mild to moderate atopic dermatitis

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06309355
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06309355 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.